Interferon β1a and depression in secondary progressive MS: Data from the SPECTRIMS Trial
- 10 September 2002
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (5) , 744-746
- https://doi.org/10.1212/wnl.59.5.744
Abstract
Depression is a suspected side effect of treatment with interferon β1a in MS. However, an association with depression has not been confirmed by rigorous studies. During the SPECTRIMS clinical trial of interferon β1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon β1a or with placebo. No significant differences between groups emerged during 36 months of follow-up. These data suggest that depression is not a side effect of interferon β1a.Keywords
This publication has 8 references indexed in Scilit:
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta treatment of multiple sclerosisNeurology, 1994
- Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideationAmerican Journal of Psychiatry, 1985
- A scaled version of the General Health QuestionnairePsychological Medicine, 1979
- The CES-D ScaleApplied Psychological Measurement, 1977
- Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisPublished by Elsevier